

1642

1.8w



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
11245/46902

Application Number 10/040,128	Filing date January 2, 2002	Examiner Nickol, Gary B.	Art Unit 1642
Invention Title:	ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY		

Address to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on :

Date: March 3, 2005
By: Lawrence P. Casson
Lawrence P. Casson (Reg. No. 46,606)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated:

March 3, 2005

By:

Lawrence P. Casson
Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO - 1449 FORM	ATTY. DOCKET NO.	SERIAL NO.
	11245/46902	10/040,128
	APPLICANT LIAO, et al.	
FILING DATE January 2, 2002	GROUP 1642	

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	4,946,778					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Ali et al., Microcirculation 4:267-277 (1997)
	Berman et al., EMBO J. 7:727-738 (1988)
	Bowie et al., Science, 247:1306-1310 (1990)
	Burgess et al., J. of Cell Bio. 111:2129-2138 (1990)
	Catalogue of Cell Lines and Hybridomas, "Fifth edition (1985) Rockville, M.D., USA
	Cole, et al., 1985, In Monoclonal Antibodies and Cancer therapy, Alan R. Liss, Inc., pp. 77-96
	Gillman & Smith, Gene 8:81-97 (1979)
	Gotsch et al., J. Cell Sci. 110:583-588 (1997)
	Gumbiner, B., & Simons, K., Cell Biol. 102:457-468 (1996)
	Kohler & Milstein, Nature, 256:495-497 (1975)
	Kozbor et al., Immunology Today 4:72, (1983)
	Lampugnani et al., J. Cell Biol. 129:203-217 (1995)
	Lazar et al., Molecular and Cellular Biology 8:1247-1252 (1988)
	Nagar et al., Nature 380:360-364 (1996)
	Overduin et al., Science 267:386-389 (1995)
	Queen, Nature 351:501 (1991)
	Remington's Pharmaceutical Science, 15 th Ed., Mack Publishing Company (1980)
	Roberts, et al., Nature 328:731-734 (1987)
	Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989)
	Scopes, Protein Purification, Springer-Verlag, N.Y. (1982)
	Williams & Barclay In: Immunoglobulin Genes, Honjo, Alt, and Rabbits, eds., (1989)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	